NRAS and breast cancer: A total of 3795 patients were included in the analysis, of which 982 had colorectal cancer with 421 KRAS‐positive cases and 36 NRAS‐positive cases, 1246 had breast cancer with 410 PIK3CA‐positive cases, and 1567 had non‐small cell lung cancer with 300 EGFR‐positive cases.